Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Retained Earnings (2017 - 2025)

Crinetics Pharmaceuticals has reported Retained Earnings over the past 9 years, most recently at -$1.4 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 48.87% year-over-year to -$1.4 billion; the TTM value through Dec 2025 reached -$1.4 billion, down 48.87%, while the annual FY2025 figure was -$1.4 billion, 48.87% down from the prior year.
  • Retained Earnings for Q4 2025 was -$1.4 billion at Crinetics Pharmaceuticals, down from -$1.3 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at $1.6 million in Q2 2025 and troughed at -$1.4 billion in Q4 2025.
  • A 5-year average of -$400.1 million and a median of -$245.9 million in 2021 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: crashed 3284750.0% in 2022 and later soared 953.16% in 2025.
  • Year by year, Retained Earnings stood at -$275.3 million in 2021, then soared by 98.57% to -$3.9 million in 2022, then surged by 124.85% to $977000.0 in 2023, then plummeted by 97552.41% to -$952.1 million in 2024, then tumbled by 48.87% to -$1.4 billion in 2025.
  • Business Quant data shows Retained Earnings for CRNX at -$1.4 billion in Q4 2025, -$1.3 billion in Q3 2025, and $1.6 million in Q2 2025.